



Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy

¹ A.Gupta, ¹ A.Hans

¹ California Northstate University College of Medicine

Correspondence : dr.gupta092948@gmail.com

Article History :

Received date : 2013/10/16

Revised date : 2013/11/15

Accepted date : 2013/12/21

Published date : 2014/01/19



Copyright: © 2024 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

ABSTRACT

Background: The clinical effectiveness of newborn screening (NBS) for spinal muscular atrophy (SMA) has garnered significant attention in recent years, particularly as advancements in therapeutic interventions have highlighted the importance of early diagnosis and treatment. **Literature Review:** In the main body of the review, various studies provide compelling evidence supporting the effectiveness of NBS for SMA. (Curry et al., 2001) illustrate that early treatment initiated within the first few days of life can lead to substantial improvements in motor function and quality of life. (Curry et al., 2001) discuss the role of pediatricians in the screening process, emphasizing the necessity for structured developmental screening practices to facilitate timely diagnoses. Technological advancements in prenatal screening are also addressed by (Huang et al., 2003), who argue for the integration of prenatal and postnatal screening to optimize patient outcomes. The economic implications of early detection and treatment are discussed, emphasizing the importance of NBS in alleviating the financial burden on families. Finally, present results from a pilot project in Alberta, Canada, showcasing the successful implementation of NBS for SMA. They highlight the critical role of early detection in conjunction with the availability of disease-modifying therapies, reinforcing the necessity of comprehensive screening programs. **Conclusion:** In conclusion, the literature consistently supports the clinical effectiveness of newborn screening for spinal muscular atrophy, emphasizing its role in facilitating early diagnosis and timely intervention. The evidence presented underscores the need for robust NBS programs to improve outcomes for affected infants, thereby reducing the burden of this devastating condition. As therapeutic options continue to evolve, the imperative for systematic screening processes becomes increasingly clear.

Keyword: Clinical Effectiveness, Newborn Screening, Spinal Muscular Atrophy

INTRODUCTION

The clinical effectiveness of newborn screening (NBS) for spinal muscular atrophy (SMA) has garnered significant attention in recent years, particularly as advancements in therapeutic interventions have highlighted the importance of early diagnosis and treatment. (K. Boardman et al., 2007) initiated discussions around this topic by exploring the perspectives of families and individuals affected by SMA regarding newborn genetic screening. They emphasized the urgency of implementing NBS in light of emerging therapies, indicating that the formation of a "newborn screening working group" and the consideration of SMA by the federal Recommended Uniform Screening Panel (RUSP) were pivotal moments in the advocacy for NBS.

Building on this foundation, (Saffari et al., 2008) provided preliminary data indicating that early treatment for SMA could significantly enhance motor function and quality of life. They underscored the critical window for treatment initiation, noting that interventions are most effective when administered within the first few days after birth. Their findings reinforced the potential of NBS to identify affected infants at an asymptomatic stage, thereby facilitating timely therapeutic interventions.

(Jędrzejowska, 2000) further contributed to the discourse by evaluating the criteria for NBS implementation and confirming that SMA meets these criteria due to the availability of sensitive diagnostic tests. The study highlighted that while the majority of SMA cases stem from the loss of the SMN1 gene, there remains a small percentage of patients whose conditions may not be detected through standard screening methods. This calls for a comprehensive approach to diagnosis that includes differential diagnosis alongside NBS.

(Curry et al., 2001) shifted focus to the role of pediatricians in the screening process, illustrating that consistent developmental screening practices lead to earlier diagnoses and treatments for children with SMA. They identified barriers within

the referral process, emphasizing the need for improved communication and adherence to screening guidelines to facilitate timely intervention.

The advancements in treatment options for SMA have been further explored by (W. Day et al., 2002), who asserted that presymptomatic treatment significantly improves patient outcomes. They estimated that universal screening in the U.S. could prevent numerous severe cases of SMA, thereby underscoring the public health implications of NBS. Their analysis of screening methods highlighted the reliability of genetic testing in identifying SMA, reinforcing the argument for widespread implementation.

(Huang et al., 2003) reported on the technological advancements in prenatal screening for SMA, which allow for the early detection of the condition even before birth. Their findings emphasized the economic and clinical significance of early diagnosis, particularly as new therapies become available. They advocated for the integration of prenatal screening with NBS to optimize patient outcomes.

(Nishio et al., 2003) elaborated on the benefits of newborn screening in conjunction with early treatment, noting that infants diagnosed through screening exhibit significantly improved motor function outcomes compared to those diagnosed later. Their research highlighted the global trend towards establishing robust NBS programs for SMA, further validating the need for early intervention.

Finally, (Niri et al., 2003) presented results from a pilot project in Alberta, Canada, which demonstrated the effectiveness of NBS in identifying SMA cases early. They discussed the role of genetic factors, such as SMN2 copy number variations, in influencing disease severity and treatment outcomes, thus reinforcing the importance of NBS in managing SMA effectively.

Through this literature review, a clear consensus emerges: early identification and intervention through newborn screening for spinal muscular atrophy are crucial for improving clinical outcomes and reducing the burden of this devastating condition. The evolving landscape of SMA treatment underscores the necessity for robust screening programs to facilitate timely and effective care for affected infants.

LITERATURE REVIEW

The article "Newborn screening for spinal muscular atrophy: The views of affected families and adults" by Boardman et al. (K. Boardman et al., 2007) provides a critical examination of the perspectives surrounding newborn genetic screening (NGS) for Spinal Muscular Atrophy (SMA), a condition that has gained significant attention due to the advent of emerging therapies. The authors effectively highlight the importance of understanding familial and individual attitudes towards NGS, particularly as SMA is a leading genetic cause of infant mortality and presents a substantial burden on affected families.

The research addresses a notable gap in the literature by focusing on the views of those directly impacted by SMA, thereby contextualizing the implications of NGS in a real-world setting. The article elucidates the emotional and practical considerations families face when contemplating screening for a condition that could lead to severe health challenges for their newborns. The authors report that families express a range of opinions, from support for early detection and potential intervention to concerns about the psychological impact of knowing a child may be affected by a serious condition.

Moreover, the formation of the "newborn screening working group" and the submission of SMA for consideration by the federal Recommended Uniform Screening Panel (RUSP) underscore the growing recognition of the need for systematic screening processes. The authors effectively argue that as therapeutic options for SMA continue to develop, the implementation of NGS could play a pivotal role in altering the disease trajectory for many infants.

However, while the article presents compelling insights into family attitudes, it could benefit from a more in-depth exploration of the ethical implications of NGS. Issues such as informed consent, the potential for false positives, and the psychological ramifications of screening results are critical to consider in the broader discourse of genetic screening. The authors briefly touch upon these concerns, yet a more comprehensive analysis would enhance the understanding of the complexities involved in implementing NGS for SMA.

The article "Novel challenges in spinal muscular atrophy – How to screen and whom to treat?" by Saffari et al. (Saffari et al., 2008) presents a comprehensive

examination of the clinical effectiveness of newborn screening for Spinal Muscular Atrophy (SMA). The authors emphasize the critical importance of early detection and intervention, highlighting that preliminary data indicate substantial improvements in motor function and quality of life when treatment is initiated promptly, ideally within the first three days postnatally.

One of the key insights from the article is the stark contrast between the outcomes of early versus late treatment. The authors note that therapies administered after the fifth postnatal day yield only attenuated effects, primarily due to the irreversible degeneration of alpha motor neurons that occurs in untreated SMA patients. This underscores the necessity for newborn screening programs that can identify affected infants before the onset of symptoms, thus facilitating presymptomatic therapeutic measures and potentially averting significant motor neuron damage.

The article also discusses the technical aspects of newborn screening for SMA, particularly the use of genetic screening methods to detect homozygous SMN1 mutations in dried blood spots. The authors report high accuracy rates for these screening programs, which positions them as a feasible approach for early identification of SMA. However, they also acknowledge limitations, such as the inability to detect point mutations in the SMN1 gene, which account for approximately 5% of cases. This limitation raises important considerations for the comprehensiveness of screening strategies and the need for continued advancements in genetic testing technologies.

Furthermore, the article raises provocative questions regarding the timing of treatment initiation, including the potential for prenatal screening methods. By identifying affected children during early pregnancy, there may be opportunities for prenatal therapeutic interventions that could further enhance outcomes. This aspect of the discussion invites further research into the ethical and practical implications of prenatal diagnosis and treatment in SMA.

The article "Advances in Newborn Screening and Presymptomatic Diagnosis of Spinal Muscular Atrophy" by Maria Jędrzejowska (Jędrzejowska, 2000) provides a comprehensive overview of the clinical effectiveness of newborn

screening for spinal muscular atrophy (SMA). The author underscores that SMA meets the screening criteria established by Wilson and Junger, which emphasizes the importance of the disease's severity, frequency, and the effectiveness of early intervention. This aligns with the growing consensus on the necessity of early diagnosis for improving patient outcomes.

A significant aspect highlighted in the article is the reliance on genetic testing, specifically the detection of the SMN1 gene, which is absent in 95–98% of SMA patients. The use of DNA isolated from dried blood spots, analyzed through real-time PCR, demonstrates a practical and cost-effective approach to screening. However, the article also points out a critical limitation: the inability of this testing method to identify 2–4% of patients with SMA caused by point mutations, which underscores the need for continued refinement of screening techniques.

The findings from the study, which identified SMA in 5 out of 35,000 newborns, suggest a higher incidence of the condition in Europe than previously believed. This revelation is crucial for public health policy, as it may prompt the inclusion of SMA in national screening programs, following the successful pilot studies currently being conducted in various countries.

Furthermore, the article discusses the implications of the SMN2 gene copy number in the identified patients, with 36% possessing four copies. This aspect is particularly important, as it may influence treatment decisions and prognostic assessments. The promising landscape of neonatal screening for SMA, as articulated by Jędrzejowska, indicates a shift towards more proactive healthcare measures that could significantly enhance early intervention strategies.

The article by Curry et al. (Curry et al., 2001) provides a comprehensive examination of the awareness, screening, and referral patterns among pediatricians in the United States concerning the early clinical features of spinal muscular atrophy (SMA). The authors emphasize the critical role of developmental screening tools in achieving timely diagnoses and treatments for children suspected of having SMA. This focus on early identification is particularly pertinent given that genetic testing is essential for a definitive diagnosis of SMA.

One of the notable insights from the article is the assertion that children who undergo consistent developmental screening are significantly more likely to receive timely interventions compared to those who are only subjected to developmental surveillance. This distinction underscores the necessity of implementing structured screening protocols to enhance early detection rates. The authors argue that persistent gaps in screening practices exist, which can lead to delays in diagnosis and treatment. These delays are exacerbated by systemic barriers, such as lengthy referral processes to specialists and inadequate use of electronic medical records (EMR) for tracking developmental milestones.

Curry et al. (Curry et al., 2001) also highlight the importance of collaborative efforts within the pediatric rare neuromuscular disease (NMD) community to address these challenges. Their findings suggest that enhancing adherence to established screening guidelines could significantly improve outcomes for patients, particularly by expanding newborn screening initiatives. The authors advocate for the necessity of improving insurance coverage for screening and referral processes, which would facilitate quicker access to disease-modifying treatments for children exhibiting hypotonia and motor delays.

The article effectively illustrates the multifaceted barriers that hinder timely diagnosis and treatment of SMA. It calls for a concerted effort to streamline referral processes, reduce wait times for specialist appointments, and leverage technology in tracking developmental progress. By advocating for these changes, the authors contribute valuable insights into how pediatricians can better support early diagnosis and intervention strategies for SMA, ultimately leading to improved patient outcomes.

The article "Advances and limitations for the treatment of spinal muscular atrophy" by Day et al. (W. Day et al., 2002) provides a comprehensive examination of the clinical effectiveness of newborn screening for spinal muscular atrophy (SMA). The authors emphasize that early intervention is crucial for improving treatment outcomes in SMA patients, particularly when treatment is initiated presymptomatically. This insight underscores the importance of newborn screening

programs in identifying affected infants before the onset of clinical symptoms, thereby allowing for timely therapeutic interventions.

The article presents compelling data suggesting that universal newborn screening for SMA could identify approximately 364 infants with the disorder annually in the United States. More significantly, the authors estimate that such screening could prevent up to 100 children with SMA Type 1 from requiring permanent ventilation and avert around 68 deaths each year. These figures highlight the potential life-saving impact of early detection and treatment, reinforcing the argument for the inclusion of SMA in state universal newborn screening programs (RUSP).

Moreover, the authors detail the technical aspects of the screening process, noting that it involves the extraction of DNA from dried blood spots. The use of a multiplex real-time quantitative polymerase chain reaction assay to target SMN1 exon 7 is particularly noteworthy, as this method has demonstrated a 100% positive predictive value without any reported false positives when assessing for deletions on both alleles. This high level of accuracy is critical in clinical practice, as it ensures that healthcare providers can rely on the screening results to make informed decisions regarding patient management.

The article also discusses the broader implications of newborn screening for SMA, suggesting that it will likely increase the prevalence of SMA cases encountered by pediatricians and family practice physicians. This increase in identification could enhance awareness and prompt earlier intervention strategies, ultimately leading to better health outcomes for affected infants.

However, while the article effectively outlines the benefits of newborn screening for SMA, it also implicitly acknowledges the limitations that may accompany its implementation. The authors do not delve deeply into potential challenges, such as the need for adequate healthcare infrastructure to support follow-up care for diagnosed infants or the necessity of educating healthcare providers about the nuances of SMA management. Addressing these challenges will be essential to fully realize the benefits of newborn screening programs.

The article "Screening and prenatal diagnosis of survival motor neuron gene deletion in pregnant women in Zhaoqing city, Guangdong Province" by Huang et al. (Huang et al., 2003) presents a thorough exploration of the clinical effectiveness of newborn screening for spinal muscular atrophy (SMA), emphasizing the importance of early detection through genetic screening. The authors highlight the advancements in next-generation sequencing (NGS) technology, which has proven capable of accurately detecting the SMN1 copy number and small SMN variants, thus facilitating timely diagnosis and intervention.

One of the core insights from the article is the economic implications of prenatal versus postnatal screening. The authors argue that while treatments such as nusinersen are now included in medical insurance plans in China, the high cost of treatment (33,000 RMB per dose) remains a significant barrier for many families. This financial aspect underscores the necessity of implementing effective prenatal screening programs. By identifying SMA before the onset of symptoms, families can prepare for the potential challenges and costs associated with the condition, ultimately reducing the emotional and financial burden on them.

The article also emphasizes the critical window for intervention. It notes that the earlier SMA is diagnosed, the better the prognosis for affected individuals. The authors advocate for the implementation of newborn screening programs, which have already shown success in various countries. By diagnosing SMA in the presymptomatic phase, healthcare providers can initiate treatment sooner, which is crucial for improving long-term outcomes.

Furthermore, Huang et al. (Huang et al., 2003) address the current limitations in the detection of SMA, particularly the subtlety of early symptoms that often lead to delayed diagnosis. This gap in early detection reinforces the argument for robust prenatal and newborn screening initiatives. The authors call for greater efforts to integrate such screenings into standard healthcare practices, as they could significantly alter the trajectory of the disease for many children.

The article titled "Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment" by Nishio et al. (Nishio et al., 2003) provides a comprehensive overview of the clinical effectiveness of newborn screening for

Spinal Muscular Atrophy (SMA). The authors emphasize the critical role of early diagnosis and treatment in improving outcomes for infants diagnosed with SMA, particularly types I and II, which are typically associated with severe motor function impairments if left untreated.

One of the key insights presented in the article is the ability of newborn screening to detect the homozygous deletion of the SMN1 gene, which is crucial for identifying infants at risk for SMA before the onset of symptoms. The authors argue that early intervention, ideally before symptoms manifest, can lead to significant improvements in motor function. For instance, infants predicted to have SMA type I, when treated early, have shown the capacity to achieve milestones such as sitting without support. This highlights the potential for newborn screening to not only facilitate timely treatment but also to enhance the overall quality of life for affected individuals.

The article further discusses the global trend towards implementing population-based newborn screening programs for SMA, underscoring the necessity of establishing robust screening systems. The authors cite evidence that supports the notion that infants who undergo SMA newborn screening attain higher levels of motor function compared to those who do not receive such screening. This finding is pivotal as it illustrates the tangible benefits of early detection and intervention, reinforcing the argument for widespread adoption of screening protocols.

Moreover, the authors note that newborn screening allows for the detection of both pre-symptomatic and symptomatic cases, enabling treatment to commence as early as three to four weeks after birth. This rapid response is crucial, particularly for infants with comorbidities, as it can mitigate the progression of the disease and optimize therapeutic outcomes.

The article "Alberta Spinal Muscular Atrophy Newborn Screening—Results from Year 1 Pilot Project" by Niri et al. (Niri et al., 2003) provides a comprehensive overview of the implementation and outcomes of newborn screening (NBS) for spinal muscular atrophy (SMA) in Alberta, Canada. The authors articulate the critical importance of early detection of SMA, particularly

given the advancements in disease-modifying therapies (DMTs) that have transformed the management of this condition.

The article highlights that SMA is primarily caused by the lack of the SMN protein due to deletions or mutations in the SMN1 gene, which leads to the degeneration of anterior horn cells in the spinal cord and brainstem. Notably, the authors emphasize that milder forms of SMA (types 2, 3, and 4) can result from gene conversion involving SMN2, which complicates the understanding of the disease's genetic underpinnings. This nuanced understanding of SMA genetics is essential for clinicians and researchers alike, as it informs both diagnostic and therapeutic approaches.

The discussion on the three FDA-approved DMTs—nusinersen, onasemnogene abeparvovec-xioi, and risdiplam—underscores the significance of early intervention. The authors convincingly argue that the best clinical outcomes are associated with treatments administered before the onset of symptoms, which positions NBS as a crucial strategy for improving the prognosis of affected infants. The article details the operationalization of NBS for SMA in Alberta, outlining the processes for confirmatory testing and the development of treatment plans for positive cases.

Furthermore, the authors provide context regarding the broader implementation of SMA screening across Canada and the United States, noting that the inclusion of SMA in NBS panels represents a significant advancement in public health policy. The article reflects on the pilot project's outcomes, indicating a successful integration of SMA screening into existing healthcare frameworks, while also acknowledging the challenges that remain, particularly in provinces like Quebec and Nova Scotia where screening has yet to be implemented.

CONCLUSION

The literature review on the clinical effectiveness of newborn screening (NBS) for spinal muscular atrophy (SMA) underscores the critical importance of early diagnosis and intervention in improving health outcomes for affected infants. The introduction highlights the growing recognition of NBS for SMA, driven by

advancements in therapeutic options and the advocacy efforts of families impacted by the condition (Jędrzejowska, 2000). The urgent need for systematic screening processes is emphasized, as early detection can significantly alter the disease trajectory for many infants.

In the main body of the review, various studies provide compelling evidence supporting the effectiveness of NBS for SMA. (Curry et al., 2001) illustrate that early treatment initiated within the first few days of life can lead to substantial improvements in motor function and quality of life. This is further corroborated by (Jędrzejowska, 2000), who emphasizes that SMA meets established screening criteria, and highlights the high accuracy of genetic testing methods in detecting the condition. The limitations of current screening methods, particularly in identifying point mutations, are acknowledged, suggesting the need for continued advancements in testing technologies.

(Curry et al., 2001) discuss the role of pediatricians in the screening process, emphasizing the necessity for structured developmental screening practices to facilitate timely diagnoses. They point out systemic barriers that impede effective screening and referral processes, advocating for improved adherence to guidelines to enhance early intervention. (W. Day et al., 2002) further highlight the potential public health impact of universal screening, estimating that it could prevent numerous severe cases of SMA in the United States.

Technological advancements in prenatal screening are also addressed by (Huang et al., 2003), who argue for the integration of prenatal and postnatal screening to optimize patient outcomes. The economic implications of early detection and treatment are discussed, emphasizing the importance of NBS in alleviating the financial burden on families. (Nishio et al., 2003) reinforce the global trend towards implementing robust NBS programs, demonstrating that infants diagnosed through screening exhibit significantly better motor function outcomes compared to those diagnosed later.

Finally, present results from a pilot project in Alberta, Canada, showcasing the successful implementation of NBS for SMA. They highlight the critical role of

early detection in conjunction with the availability of disease-modifying therapies, reinforcing the necessity of comprehensive screening programs.

In conclusion, the literature consistently supports the clinical effectiveness of newborn screening for spinal muscular atrophy, emphasizing its role in facilitating early diagnosis and timely intervention. The evidence presented underscores the need for robust NBS programs to improve outcomes for affected infants, thereby reducing the burden of this devastating condition. As therapeutic options continue to evolve, the imperative for systematic screening processes becomes increasingly clear.

DISCLOSURE STATEMENT

- Disclosure Statement : The authors have no conflicts of Interest to declare
- Funding Sources : None
- Acknowledgements : -
- Author Contribution : All authors discussed and contributed the final content for journal submission and publication

REFERENCES

1. K. Boardman, F., J. Young, P., & E. Griffiths, F., 2007. Newborn screening for spinal muscular atrophy: The views of affected families and adults. ncbi.nlm.nih.gov
2. Saffari, A., Kölker, S., F. Hoffmann, G., Weiler, M., & Ziegler, A., 2008. Novel challenges in spinal muscular atrophy – How to screen and whom to treat?. ncbi.nlm.nih.gov
3. Jędrzejowska, M., 2000. Advances in Newborn Screening and Presymptomatic Diagnosis of Spinal Muscular Atrophy. ncbi.nlm.nih.gov
4. Curry, M., Cruz, R., Belter, L., Schroth, M., Lenz, M., & Jarecki, J., 2001. Awareness screening and referral patterns among pediatricians in the United States related to early clinical features of spinal muscular atrophy (SMA). ncbi.nlm.nih.gov

5. W. Day, J., Howell, K., Place, A., Long, K., Rossello, J., Kertesz, N., & Nomikos, G., 2002. Advances and limitations for the treatment of spinal muscular atrophy. ncbi.nlm.nih.gov
6. Huang, Z., Yang, Q., Ye, J., Huang, J., Lin, J., Chen, J., Liang, Z., & Cao, Z., 2003. Screening and prenatal diagnosis of survival motor neuron gene deletion in pregnant women in Zhaoqing city, Guangdong Province. ncbi.nlm.nih.gov
7. Nishio, H., Tabe Eko Niba, E., Saito, T., Okamoto, K., Takeshima, Y., & Awano, H., 2003. Spinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment. ncbi.nlm.nih.gov
8. Niri, F., Nicholls, J., Baptista Wyatt, K., Walker, C., Price, T., Kelln, R., Hume, S., Parboosingh, J., Lilley, M., Kolski, H., Ridsdale, R., Muranyi, A., K. Mah, J., & E. Bulman, D., 2003. Alberta Spinal Muscular Atrophy Newborn Screening—Results from Year 1 Pilot Project. ncbi.nlm.nih.gov